Invokana (in-vo-KAHN-uh, canagliflozin), as the first in a new class of oral drugs for type 2 diabetes
Reps will promote Invokana (in-vo-KAHN-uh, canagliflozin), as the first in a new class of oral drugs for type 2 diabetes.
You'll hear it referred to as an "SGLT2 inhibitor"...because it inhibits sodium-glucose co-transporter 2 in the kidneys.
This allows more glucose to spill into the urine instead of being reabsorbed.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive